Ponce, Kiarrah Jewelrich S.

HRN: 22-64-32  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/24/2023
CEFUROXIME 750MG (VIAL)
02/24/2023
03/02/2023
IV
650mg
Q8Hrs
Intestinal Amoebiasis; UTI
Waiting Final Action 
02/24/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/24/2023
03/02/2023
IV
325mg
Q8Hrs
Intestinal Amoebiasis; UTI
Waiting Final Action 
02/26/2023
CEFTRIAXONE 1G (VIAL)
02/26/2023
03/04/2023
IVT
830mg
Q12
UTI
Waiting Final Action 
03/01/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/01/2023
03/06/2023
IVT
1.9
Q8
Uti
Waiting Final Action 
03/02/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/02/2023
03/08/2023
SLOW IV
146mg
Q12
T/C Sepsis Prob Sec To Typhoid Fever
Waiting Final Action 
03/03/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/03/2023
03/05/2023
IV
325 Mg
Q8hrs
Intestinal Amoebiasis
03/04/2023
CIPROFLOXACIN 500MG (TAB)
03/04/2023
03/10/2023
PO
500mg
BID
UTI
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: